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INTRODUCTION
Endoscopic assessments of extension, grade of inflammation and mucosal healing (MH) as well as early detection of neoplastic colonic lesions are important key parameters for management of patients with inflammatory bowel disease (IBD). Indeed, mucosal and histological healing predicts sustained clinical and steroid free remission, and avoids complications, hospitalisation and surgery. There is an emerging strategy in some countries to consider stopping or de-escalating biological therapy in patients with IBD to reduce side effects and cost burden. Endoscopic MH is a key endpoint to achieve before considering exit strategy from targeted therapies. (1) . In general, patients in clinical, biomarker, and endoscopic remission are more likely to remain well when treatment is de-escalated. However, there is still not an ideal validated definition of endoscopic MH in IBD. The current endoscopic scoring systems, used in the clinical practice, to assess severity of inflammation in IBD were not designed to reflect endoscopic features of MH. They have some limitations, cannot detect and assess mild patchy inflammatory mucosal changes and differentiate well between quiescient and mild activity of the disease. Importantly, most of these endoscopic scores have been developed with the previous generation standard white light endoscopes (WLE). (2) With the new advanced high definition (HD) endoscopic technologies, optical diagnosis Narrow Banding Imaging (NBI, Olympus Japan) Optical enhancement iSCAN (iSCAN -OE Pentax , Japan) , Blue Laser Image ( BLI , Fujifilm Japan) and Confocal Laser Endomicroscopy ( CLE, Mauna Kea France), endocytoscope ( Olympus ,Japan ) and the emerging endoscopic molecular labeling, modern endoscopy can attain optical characterisation reflecting histology better. In Crohn's disease, the need for a new consensus to define mucosal healing is clearly required as discussed in details as a viewpoint recently by Bossuyt et al (REF) . It is still debated how surveillance should be optimally performed to increase the detection rate of colonic neoplasia in patients with IBD and better characterise lesions. Dye chromoendoscopy (DCE) is considered the standard endoscopic technique following the SCENIC consensus statementsguidelines. While DCE with targeted biopsies currently provides the best lesion detection yield in long standing UC, there is growing evidence that in future well trained colonoscopists using HD equipment with optical and digital enhancements may be able to obtain equivalent yield without pan-colonic dye spraying. (3) . We discuss below how such new techniques, combined with new endoscopic advanced endoscopic resection techniques (mucosal and submucosal resection) promises to limit the number of colectomies in the presence of dysplasia. (4) We have not considered small bowel enteroscopy or video capsule enteroscopy in this review where advanced imaging technologies have not been widely applied. We have not discussed advanced therapeutic procedures such as dilation of strictures but these have been discussed in recent references (REF Shen Bo)
2.CURRENT STATUS OF ENDOSCOPIC AND HISTOLOGICAL HEALING IN UC AND CD
MH is an important therapeutic endpoint to achieve in IBD and is now widely accepted as a reliable target for optimum management of IBD patients (Selecting therapeutic targets in inflammatory bowel disease). STRIDE) (5) . The terms MH and "deep remission"(clinical + endoscopic) are considered new therapeutic targets in the treatment of IBD patients. MH is a term used interchangeably with endoscopic healing though in future these two terms may become more specific. (5) At present there is no clear endoscopic definition of MH when WLE is used, and the lower end of endoscopic inflammation assessment scale is considered de facto MH. In the clinical trials Mayo Endoscopic Score (MES) 0 and 1 are considered to represent MH, but 0 is better than 1 and should be the optimal goal to aim for. (6) (7) (8) 18) Carvalho et al reported that in patients with left-sided or extensive colitis, MES 1 was associated with an increased risk of clinical relapse compared with MES 0 (27.3% versus 11.5% p= 0.022) as well as increased risk of steroids or immunosuppressant drugs and hospitalisation (13.0% versus 3.3% p=0.044. Clearly using MES 1 has limitations when considering MH. (6) The time period for observation was at 12 months after total colonoscopy.
The exact histological definition of MH continues to evolve and the most appropriate definition of histological remission has yet to be determined and currently is not considered as a target in UC (STRIDE) (5) . However histological assessment in addition to HD white light colonoscopy is considered a sensitive measure of the absence of inflammation and there are evolving histological classifications being developed such as Robarts histological index (RHI) and NANCY histological score that aim to better define remission. (9, 10) .
(A) Current Endoscopic scoring systems in UC and their limitations
Several scoring systems have been developed using WLE some of which require further validation and noneall of these have not included the specific endoscopic features and definition of MH. The Mayo endoscopic score (MES) is the most commonly used in the clinical practice and trials and more recently other scoring systems have been developed and validated such as the Ulcerative Colitis Endoscopic Index Severity (UCEIS) and The Ulcerative Colitis Colonoscopic Index of Severity (UCCIS). (11, 12, 13, 18) Table 1 Travis et al. proposed the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) -based on WLE as a reliable and validated score of endoscopic severity in UC as an alternative to the MES. (12) . UCEIS takes into account three endoscopic findings -vascular pattern, bleeding, and erosions/ulcers. It is a useful tool in clinical practice and is starting to be adopted routinely in central readouts for clinical trials. However, it also has several limitations as the definition of MH and the threshold for mild to moderate and severe disease are not clearly described, the disease extension is not evaluated and advantage in the inter-observer agreement over MES has not yet been demonstrated.
The Ulcerative Colitis Colonoscopic Index of Severity (UCCIS) was recently proposed to overcome these limitations and to include disease extension but is more complex,, has not been adopted in daily practice and is not validated in large studies yet. (13) Some of the components of these scores such as vascular pattern are now outdated as newer generation of endoscopes demonstrate abnormal vascular patterns rather than loss or obliterated vascular pattern and friability, in severe disease as well as in mild disease (12 13) . Regenerative changes and scarring/drop out of pits have generally not been considered with WLE. Therefore there is a need for new or adapted endoscopic scoring systems that are relevant to the current generation of HD endoscopes equipped with electronic virtual chromoendoscopy (VCE).
(B) Current endoscopic scoring systems in Crohn's disease and their limitations
In CD the inflammation is transmural and MH is considered as minimum goal for successful mucosal endpoint (STRIDE).(5) The assessment of inflammation in CD requires multiple cross sectional radiological imaging (MR or CT enterography, preferably the former) and/or mucosal endoscopic evaluation to ensure complete healing after therapy (including enteroscopy).
The most common endoscopic scoring indices are the CD Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for CD (SES-CD). (14, 15) However, the operating characteristics in terms of validation, responsiveness and reliability of these endoscopic indices to assess inflammation and predict outcome in CD is not clear yet. Potential limitations of these endoscopic scores are that these do not include the definition of MH, and the complexity of calculation make these score difficult to be adopted in daily clinical practice. Recently Khanna et al have also assessed the responsiveness of the CDEIS and SES-CD using data from a trial of adalimumab. The SES-CD demonstrated numerically greater response to treatment and compared to CDEIS, stronger correlation with the global evaluation of lesion severity (GELS), and is less cumbersome to calculate. (16) However, the exact threshold of SES-CD to define response to therapy as endoscopic endpoint in clinical trials ,the general lack of clear definition of MH and of adoption in clinical practice remain limitations.
The Rutgeerts score for postoperative CD recurrence was developed 1990 by examining 89 patients with ileal resection for CD and observing clinical outcomes in patients with early neo-terminal ileum lesions. A 5-grade stepwise numeric ulcers index gradation of endoscopic postoperative recurrence in the neoterminal ileum were developed (17) Although the score has been adopted in both trials and clinical practice, only a few very recent studies have explored intra-and inter-observer agreement, but lack robust formal validation, Another limitation of the Rutgeerts' score is when the anastomosis cannot be reached and passed, the neo-terminal ileum cannot be assessed. Clear distinction between inflammatory and suture or ischaemic ulcers is difficult. Further new development and more detailed scoring systems are required in the future, especially as all the scores were defined using WLE only .(17)
3.WHAT ARE THE NEW TECHNOLOGIES THAT ARE AVAILABLE

Recent advances in endoscopic assessment in IBD include dye based Chromoendoscopy (DCE), Virtual
Electronic Chromoendoscopy (VCE), Confocal Laser Endomicroscopy (CLE), and endocytoscopy which have dramatically improved visualisation of patchy subtle mucosal changes allowing targeted biopsies and increasing the yield and characterisation of colonic dysplastic lesions in IBD. In addition, the image resolution of HD endoscopes is much improved compared to standard WLE. Thus novel endoscopy have started to show promise to approximate histologic readouts. (19) 
(A). High Definition & Dye Chromoendoscopy
HD colonoscopy is an advanced technology employing a HD monitor and high resolution charge-coupled device (CCD). HD endoscopes produce image signals with resolution of 850,000 to 2 million pixels and offer a field of vision of 170°, instead of standard-definition (SD) which produces signal images with resolutions of 100,000 to 400,000 pixels with a field of vision of 130°.
The increased resolution of HD endoscope offers an opportunity for better characterisation and definition of the borders of neoplastic lesions in IBD patients. (20) DCE is an endoscopic technique which uses the topical application of stains to improve identification and characterisation of colonic lesions during endoscopy. Common staining agents used are methylene blue as an absorptive contrast and indigo carmine as a reactive agent. (21) 
(B).Dyeless Chromoendoscopy
VCE includes optical technologies such as Narrow-Band Imaging (NBI, Olympus), Flexible Imaging Colour Enhancement (FICE, Fujinon) and I-Scan (Pentax) and can enhance details of tissue surface without any application of dye, as well as blood vessels. A direct image is obtained with the standard WLE, which uses the full visible wavelength range (400-700 nm) to produce a red-green-blue image, and with NBI, where optical filters are used to reflect the light. FICE and I-Scan methods are based on the reflection of photons to reconstruct virtual images, through a digital post-processing of the endoscopic images, without any filter application. (22) (23) (24) (25) Two new image-enhanced colonoscopes, using the LASEREO system (Fujifilm, Japan), have recently been developed: blue laser imaging (BLI) and linked colour imaging (LCI).
The BLI system is equipped with a light source (LL-4450) and a processor (VP-4450HD) with two types of diode laser and it can be used for the examination of both the micro-vessels and the mucosa.
The LCI expanded the colour range of reddish and whitish colours, therefore enhancing slight differences in the red region of the mucosa in conditions including inflammation and cancer. (23) The new i-Scan Optical Enhancement (OE) (Pentax, Japan) is a combination of optical and a digital enhancement chromoendoscopy in a single system. It consists of three different algorithms that can be selected by pressing a button on the endoscope: contrast enhancement (to digitally add blue colour to relatively dark areas), surface enhancement (to modify luminance intensity) and tone enhancement. (24) A novel endoscopic system and colonoscope with NBI capability and a "dual focus" function has recently been introduced. This enables dual-focus near-field magnification by pushing a single button to closely examine the mucosal tissue and capillary network. (25) Currently many gastroenterologists are not utilising the full potential of such advanced technologies integrated in current generation of equipment.
APPLICATIONS OF NEW TECHNOLOGIES THAT ARE AVAILABLE IN IBD (A) New paradigms to assess endoscopic inflammation and healing in IBD
Recently, many studies have showed that HD in combination with VCE can precisely assess inflammatory activity and extension of IBD disease (8, 26, 28) . With the advanced VCE systems the vessels appear not absent or obliterated but irregular and distorted especially in mild and patchy inflammation.
First ,Kudo et al have showed that NBI can contribute to the clear visualisation of Mucosal Vascular Pattern (MVPPV) in patient with UC (27) . They have showed MVPMPV to be associated with the histological severity, especially regarding acute inflammation in patients with UC. NBI could depict vessels in the deep layer, which could not be discerned by standard definition (SD)-WLE. The MVP under NBI comprises two distinctive patterns: deep vasculature as depicted green in colour, and superficial vasculature which are brown in colour. There was a significant association with acute inflammatory cells (26% versus 0% p0.0001) and goblet cell deposition (32% versus 5% p0.0006) in the segments with distorted MPVP. However , NBI has some limitations to assess moderate /severe disease where intra-mucosal bleeding is a feature due to the absorption of light by haemoglobin, but there maybe a role in predicting relapse in patients with quiescent disease. (27) . Hayashi et al have recently confirmed that that magnifying NBI observation of mucosa was effective for the assessment of UC follow-up. The endoscopic vascular pattern features were accurately assessed by NBI with magnification and were important predictors of UC relapse (28, 29) The i-SCAN system has also showed promising results. Neumann et al have showed that VCE significantly improves prediction of inflammatory activity and extent with an agreement of 53.85% and 48.71% (p0.0009) in the HD WLE group and 89.74% and 92.31% in the VCE group (p 0.066). (30) We have developed the first VCE (i-SCAN) endoscopic scoring system to assess inflammation in UC and have introduced endoscopic findings of mucosal and vascular healing. (26) A new histological scoring system (ECAP system: Extent, Chronicity, Activity, Plus additional findings) was also designed to reflect chronic and acute histological changes in UC. In patients with Mayo endoscopic sub-score of 0, 30.4 % had an abnormal mucosal pattern and 73.9 % of them had an abnormal vascular pattern on VCE. The VCE was able to pick up subtle histological abnormalities underlying the apparently healed mucosa in UC as assessed by the refined ECAP histology scoring system. (8) The PiCaSSO (Paddington International Virtual ChromoendoScopy ScOre) is a recent VCE scoring system in UC to redefine endoscopic findings of mucosal and vascular healing developed by international experts in optical diagnosis. (19) The new PICaSSO embraced all the endoscopic findings of the inflammation in UC and performed better than the previous i-SCAN score developed by Iacucci et al. The interobserver agreement of the PICaSSO score between the experts was very good in the pre-test and post-test evaluations and the accuracy of the overall PICaSSO in assessing histologic abnormalities and inflammation by Harpaz score was 57% (95% CI, 48%-65%), by RHI 72% (95% CI, 64%-79%), and by ECAP system 83% (95% CI, 76%-88%).
(19) ( video)
The PICaSSO SCORE also achieves good inter-rater agreement post-training, across all levels of endoscopy experience. Correlation between PICaSSO and histology was strong, with performance accuracy that is sustainable over time. (31) Outcomes of mucosal healing defined by PICaSSO are being assessed in a multicentre study. The Mayo endoscopic score used MES 0 or 1 as definition of mucosal healing, but it is simply the lower end of the inflammation scoring system. The PICaSSO can define mucosal healing better with both mucosal and vascular healing and correlates with histologic scores better and a training module may improve performance (31)..
Iacucci et al have also recently reported the first experience on using the newly introduced i-scan Optical
Enhancement (OE) with magnification (Pentax, Japan) to assess subtle inflammatory changes in UC. The new OE i-scan endoscopic score correlate very well with histological ECAP (r = 0.70;P < 0.001). The accuracy of the I-SCAN OE score to detect abnormalities by ECAP was 80% (sensitivity 78%, specificity 100 %). (28) , the correlation between I-SCAN OE score and RHI was r=0.61 (P < 0.01), and the accuracy to detect abnormalities by RHI was 68% (sensitivity 78%, specificity 50%). (26) The PICaSSO SCORE also achieves good inter-rater agreement post-training, across all levels of endoscopy experience. Correlation between PICaSSO and histology was strong, with performance accuracy that is sustainable over time. (31) Outcomes of mucosal healing defined by PICaSSO are being assessed in a multicentre study.
Recently, a novel imaging technique developed by Fujifilm,Japan is linked colour imaging (LCI). LCI vascular pattern classification was developed to better assess inflammation and MH in UC. The LCI score strongly correlate with histology and interobserver agreement for LCI was excellent between experts and non experts. VCE and LCI may be a novel approach for evaluating colonic MH and for predicting relapse and outcome in UC patients and guide monitoring and treatment decision ( 32) Detailed description of mucosal healing may bridge the gap between endoscopic and histologic definitions of mucosal healing. In UC especially histologic healing is increasing been highlighted as reflecting long term outcome better, but in future more precise endoscopic definitions of mucosal healing may overcome this
(B) New paradigm to detect dysplasia in IBD
In a retrospective cohort study in long-standing colonic IBD patients, HD colonoscopy was associated with a Recently, SCENIC consensus guidelines recommended DCE with targeted biopsies as the optimal modality to be adopted in the daily practice to increase the detection colonic dysplasia in patient with IBD. In the The SCENIC meta-analysis has some limitations and has considered studies using the previous generation of endoscopes with standard WLE rather the new generation of the endoscopes with HD resolution of image.
The use of the DCE has been limited mostly to low -quality observational studies and only two randomised controlled trials were conducted. Moreover, the SCENIC consensus did not recommend other endoscopic techniques such as VCE (NBI, iSCAN, BLI) because there were not yet evidence of their effectiveness in detecting dysplastic lesions in IBD patients compared with DCE. (3) Recently, a multicentre prospective cohort study from Spain has confirmed the value of DCE in 350 longstanding IBD patients undergoing surveillance colonoscopy using WLE followed by 0.4% indigo carmine DCE. Results showed a higher dysplasia miss rate with WLE, and 57.4% incremental yield for DCE.
Detection rate of dysplasia was comparable between SD and HD colonoscopies (51.5% versus 52.3%, p=0.30). Moreover, dysplasia detection rate was comparable between expert and non-expert (18.5% versus 13.1%, p=0.20) and no significant learning curve was observed (8.2% versus 14.2%, p=0.46). (38) However, the effectiveness of DCE for IBD surveillance is controversial and debated and there are still many barriers such as learning curve, cost and time as well as procedure reimbursement, are some of the main issues to resolve in order to facilitate and widely implement DCE in routine practice.
The SCENIC meta-analysis has some limitations and has considered studies using the previous generation of endoscopes with standard WLE rather the new generation of the endoscopes with HD resolution of image.
The use of the DCE has been limited mostly to low -quality observational studies and only two randomised controlled trials were conducted. Moreover, the SCENIC guidelines did not recommend other endoscopic Initial studies for dysplasia detection had explored NBI as the first introduced VCE in clinical practice. In a prospective trial from Netherlands, NBI colonoscopy did not increase the detection rate of dysplastic lesions in patients with longstanding UC. (39) A randomised cross-over trial confirmed the same results in patients with UC who underwent both NBI and HD colonoscopy within 3 weeks; of the 11 patients with neoplasia 82% were diagnosed with HD colonoscopy versus 73% by NBI (p=1.0), suggesting that NBI does not significantly improve the detection of neoplasia. (40) Moreover, in the randomised study by Pellise et al comparing HD colonoscopy plus NBI with HD colonoscopy plus DCE, no significant difference was found in the detection rates of dysplasia between the two groups. In the NBI group, however, there was a higher miss rate of dysplastic lesions as compared to DCE. (41) . Furthermore, in three trials which compared WLE and NBI colonoscopies, there was no difference in dysplasia detection rate between the two procedures. [39] [40] [41] [42] [43] .
Efthymiou et al have shown in a tandem colonoscopy trial that DCE is more sensitive than NBI in detecting lesions for target biopsy but that the overall detection of dysplasia was not different between NBI and DCE [44] . Based on these heterogeneous results in these trials SCENIC consensus guidelines have not recommended the use of VCE in the clinical practice. However, two recent randomised trial have revealed that these electronically enhanced procedures are effective in detecting neoplastic lesions also in patients with IBD.
However, two recent randomised trial have revealed that these electronically enhanced procedures are effective in detecting neoplastic lesions also in patients with IBD. produced different results than DCE in patients with UC. In this international, multi-centre prospective randomised controlled trial, patients requiring surveillance colonoscopy were randomised to chromoendoscopy or NBI. The dysplasia detection rate was not different between the two groups (21.2% CE vs. 21.5% in NBI p0.964), but DCE added an average of 7 minutes to procedure time. (46) ( Table 2) There are no published data about either the use of BLI or LCI to detect colonic lesion in IBD patients.
Further study in IBD patients are needed to understand if BLI or LCI may be useful in these patients.
(C) Endoscopic characterisation of colonic lesions in IBD
Accurate endoscopic characterisation of colonic dysplastic lesions is important for therapeutic management.
Blackstone was the first to describe the morphologic findings of the colonic dysplasia in IBD as a polypoid mass and a plaque-like lesion (47) . SCENIC consensus guidelines introduced the modified Paris classification The NPV between DCE and NBI were comparable (p=0.739). The inter-observer agreement was better with DCE (κ 0.332 Vs. 0.224 p=0.001) when using Kudo Pit Patterns. Interobserver aAgreement improved when participants were asked to differentiate neoplastic Vs non-neoplastic where NBI performed better than DCE (κ 0.653 vs. 0.495 p<0.001). Therefore, the authors found that expert endoscopists have a moderate to substantial inter-observer agreement. (49) It is still controversial whether the Kudo pit pattern can be used to predict histology of colonic IBD lesions especially in the presence of inflammation associated regenerative pattern and when assessed by using standard colonoscopes without magnification in non-experts hands . (50) Nevertheless ,the optimal method of assessing the pit pattern remains still controversial and needs to be explored in future studies ( Figures 1-3) 
(D) Therapeutic management of colonic dysplasia in IBD
The appropriate management of colonic dysplasia in IBD patients is evolving with advances in endoscopic technology and new devices. SCENIC consensus guidelines have also introduced new terminology to describe colonic lesions and the new concept of the endoscopic resectability when dysplasia appears circumscribed.
They also recommend continued post-polypectomy endoscopic surveillance as strategy. 
5.ENDOSCOPIC TECHNOLOGIES IN EVOLUTION (A) Confocal laser endomicroscopy (CLE)
CLE is a relatively new technique which allows "in vivo" microscopic evaluation of the colonic mucosa, like 'real time histology' to facilitate diagnosis and decision regarding resectability of lesions.
In the past, CLE could be performed with an endoscope-based equipment (Pentax; Tokyo, Japan; iCLE), which is no longer clinically available. In more recent studies CLE is performed using a through the scope probe (Cellvizio, Mauna Kea ; Paris, France; pCLE). During CLE image acquisition, application of fluorescent agents is necessary, either systemic (i.e., fluorescein sodium) or topical (e.g., acriflavine hydrochloride, cresyl violet acetate) to highlight cellular, subcellular, and vessel architecture (56) Many studies with CLE have shown its potential in IBD to differentiate between CD and UC, assess grade of inflammation , predict outcome and characterise colonic dysplastic lesions by targeting biopsies and directing endoscopic management . encouraging, but these were much lower than those patients having HD and NBI (100%, 89% and 92% respectively) (63). ( Figure 5) 
(i) Assessment of Disease Activity
(iii) Endoscopic molecular labelling to stratify patients for therapy
The concept of tailoring therapy to individual patients based on molecular analysis may play a key role in maximising benefits and minimising risks. The potential future use of molecular imaging to stratify IBD patients regarding response to targeted monoclonal antibody therapies is exciting but challenging.
Molecular imaging is based on the utilisation of fluorescent probes with specificity toward defined molecular targets and their visualisation by endoscopic devices such as CLE. (64, 65) The first molecular imaging study has been performed for anti-tumor necrosis factor (anti-TNF) response (66) . The study assessed the number of mTNF-expressing mucosal cells in Crohn's disease patients 'ex vivo'
and 'in vivo' after topical application of a GMP-fluorescent anti-TNF antibody (fluorescein isothiocyanate-FITC adalimumab) to the most inflamed area of the mucosa and subsequent imaging by CLE. FITC labelled monoclonal antibodies cannot be injected intravenously. There was a significant correlation between mucosal mTNF-expression and therapeutic response to subsequent therapy with adalimumab--patients with high amounts of mTNF expressing cells had a significantly higher probability of responding to anti-TNF therapy at week 12 (92%) compared with patients with low amounts of mTNF expressing cells (15%). The sensitivity and specificity for prediction were 92% and 85%, respectively. (64) Recently , molecular methods has been also been used to determine the response to vedolizumab in IBD patients by evaluating the α4β7 integrin expression (65) or to detect dysplasia in UC patients ( 66) Molecular endoscopic imaging is an exiting but still a research field and will not be adopted into clinical routine without extensive validation.
(B) Endocytoscopy
Endocytoscopy (EC) is a 'super' high-resolution endoscopic technique that enables the real-time observation of cells and nuclei of mucosal surfaces during ongoing endoscopy in vivo with magnification ranging from 450-to 1400-fold -it permits prediction of histology and direct sampling virtual biopsy Recently a new endocytoscopy system (GIF-Y0002), using only one lens, was introduced; it allows continuous increase of zooming power from the conventional endoscopy level, up to 380-fold. Endocytoscopy requires absorptive staining agents, like methylene blue, toluidine blue or cresyl violet sprayed onto the mucosa and mucolysis with N-acetylcysteine.
Bessho et al developed a score for UC assessment using EC termed The Endocystocopy System Score (ECSS), which included: A. shape of crypts; B. distance between neighbouring crypts; and C. visibility of superficial microvessels. For the total score good agreement between endoscopists was demonstrated k = 0.79 (95% CI 0.71-0.87 p<0.001). It also showed a strong correlation with histopathological grades for disease activity, (r=0.713 p<0.001) (67) . In a small study of 40 patients with IBD the concordance between EC and histology was 100%. (68) A further study aimed to identify the usefulness of endocystoscopy to assess MH in patients with UC with MES 0/1, and showed that ECSS correlated well with histology. They also demonstrated features that showed high degree of inflammatory cell infiltrates and therefore could predict relapse (69) . 
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